Vimta Labs Ltd

- Currently, there is no plan to raise funds through rights issue or other equity methods. - The company has cash of INR 650 million (as of Q4 FY26), and management feels no immediate need for fundraising via such methods. - No firm plans on debt or other capital raising methods have been disclosed. - Management will share any updates on fundraising if and when such plans materialize. - The company prefers to maintain a net debt-free balance sheet with sufficient cash reserves for uncertainties.

- Currently, there is no firm or concrete plan for raising funds through methods like rights issues for ramping up the capex, as per Harita Vasireddi (Page 13). - The company has recently moved into new facilities that are designed to support growth for the next 4-5 years (Page 11). - Utilization of the new facility is expected to pick up gradually over this year and the next (Page 11). - There are no specific plans mentioned for acquisitions or capacity expansions at present, but management will announce if something materializes (Page 12). - The newly set-up US subsidiary aims to be closer to customers rather than for tariff benefits or significant investments (Page 11). - The entry into biologics contract research and development services is a strategic milestone; investments in people, infrastructure, and equipment have already been made to support this vertical (Pages 4, 12).

- Vimta Labs aims to maintain a strong CAGR similar to the last 5-7 years, targeting INR 500 crores in annualized revenue by FY27. - Growth drivers include pharmaceuticals, food testing, and electronics, with good visibility and expanding markets. - The company anticipates continued robust demand, especially in pharma analytical and biologics contract research. - Electronics and electrical testing are expected to gain momentum post fixing leadership challenges. - Biologics contract research is set to commence in FY27, with efforts underway to onboard clients. - Expansion facilities are planned to support growth for the next 4-5 years. - Despite geopolitical and economic uncertainties, Vimta remains hopeful to sustain and grow revenue momentum. - Focus on international market expansion and increasing share in overseas pharma and food testing contracts. - Growth seen in FDA-compliant pharma testing and food testing helped Q4 revenue achieve all-time highs.

- Vimta Labs targets maintaining a strong CAGR seen over the last 5-7 years, aiming for INR 500 crores annual revenue run rate by FY27 despite some recent headwinds. - EBITDA margins are expected to stay above 35%, with possible minor fluctuations of 1-2% due to cost pressures but generally stable. - The company aims to sustain revenue momentum (INR 120-130 crores quarterly) driven by pharma and food testing divisions. - Biologics contract research, starting FY27, is expected to build traction gradually without significant immediate revenue impact. - The new US subsidiary will support customer proximity, potentially aiding future revenue growth. - Vimta remains net debt-free with INR 650 million cash, with no immediate plans for fundraising, ensuring capital for growth. - Long-term growth is supported by increasing outsourcing trends in pharma, food, and electronics sectors, alongside rising R&D and regulatory demands.

- Vimta Labs has reported good inquiries and traction for new projects. - They have promising prospects from Europe, India, and some from the US. - Finalizations for product and modality of these projects are underway. - Some biologics contract research projects are under discussion, with hopes of materializing soon. - While no concrete plans for acquisitions or major expansions are firmed up, the company is exploring potential opportunities. - Management is confident about maintaining revenue momentum with an aim to keep quarterly revenues around INR120-130 crores. - The new facility's utilization is expected to ramp up gradually over the next few years to support growth. - Overall business visibility is good, with steady pipelines across pharmaceutical, food, electronics, and biologics segments.